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Ovarian tissue cryopreservation in children with cancer
Ovarian tissue cryopreservation is now a major part of 
the strategies used to preserve fertility in prepubertal 
children given gonadotoxic treatments for cancer. Unlike 
post-pubertal patients, oocyte or embryo cryobanking 
is not appropriate for children and cryopreservation of 
ovarian tissue remains the only therapeutic option in 
most of the cases. Restoration of ovarian function after 
reimplantation of frozen–thawed mature ovarian cortex 
and reports of subsequent pregnancies were the basis 
of the rationale that guided the development of this 
approach in the treatment of childhood cancer. However, 
the success rate of the procedure in adult women is 
unknown, and the potency of cryopreserved immature 
gonads to restore fertility in adult survivors of childhood 
cancer has not yet been assessed. Nevertheless, recent 
data suggest that immature ovaries are able to restore 
hormonal function in prepubertal children, in the same 
way that mature ovaries can in adults.1,2 Additionally, 
immature ovaries have been used to restore fertility in 
experimental models.3,4 Although the conditions of tissue 
harvesting, conditioning, and storing are well supervised 
by national biomedical and bioethical frameworks, 
patient selection criteria are mainly left to the discretion 
of local multidisciplinary committees, resulting in 
substantial heterogeneity of inclusion criteria, not only 
worldwide, but also within individual countries. 
In The Lancet Oncology, Hamish Wallace and colleagues5 
address this important issue, and assess their own 
selection criteria—the Edinburgh selection criteria. 
The authors retrospectively compared the occurrence 
of premature ovarian insuﬃ  ciency over 15 years in a 
population-based study of children treated for cancer, 
who were or not oﬀ ered this procedure. They report 
that the cumulative probability of developing premature 
ovarian insuﬃ  ciency after treatment was completed was 
signiﬁ cantly higher for patients oﬀ ered ovarian tissue 
cryopreservation than for those who were not oﬀ ered 
ovarian tissue cryopreservation (15-year probability 
35% [95% CI 10–53] vs 1% [0–2]; p<0·0001; hazard ratio 
56·8 [95% CI 6·2–521·6] at 10 years), suggesting that the 
Edinburgh selection criteria accurately predicted which 
patients would or would not develop premature ovarian 
insuﬃ  ciency. Although the small number of assessable 
patients who had successfully undergone ovarian cryo-
preservation (14, compared with 141 assessable patients 
in the not-oﬀ ered group) weakened the comparison, this 
is the ﬁ rst report that aimed to assess selection criteria 
for ovarian cryopreservation in children with cancer. 
The oﬀ er of ovarian tissue cryopreservation in the 
paediatric context is especially sensitive because 
the delay between the procedure and the potential 
use of the ovarian cortex could reach decades (the 
median age at diagnosis for childhood cancer is about 
5·1 years).6 Parents are asked to plan for a future they 
cannot yet imagine, and, at the same time this request 
suggests the possibility of recovery, and so could be 
perceived as a message of hope. In this context, the 
selection criteria and follow-up protocol for paediatric 
ovarian tissue cryopreservation, as with any treatment 
protocol for children with cancer, should undergo 
evidence-based standardisation. In view of the small 
size of population of childhood cancer patients 
who could beneﬁ t from the procedure, national or 
international studies will be necessary to properly 
assess the validity of these selection criteria. 
In Wallace and colleagues’ study, the selection 
criteria and the deﬁ nition of premature ovarian 
insuﬃ  ciency were applied identically to prepubertal 
and post-pubertal patients. Because of the diﬀ erent 
sensitivity of gonads to toxic treatment at diﬀ erent 
ages,7 and the report of spontaneous recovery of 
hormonal function after premature menopause as 
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a result of treatment,8 the deﬁ nition of high-risk for 
premature ovarian insuﬃ  ciency and of premature 
ovarian insuﬃ  ciency itself, as well as the modalities 
of follow-up, should be key points of discussion in a 
process of harmonisation. Other means to preserve 
fertility, such as ovarian transposition in case of pelvic 
radiotherapy,9 should also be assessed either as an 
alternative or as a combined approach.
Almost two decades have passed since the ﬁ rst 
ovarian tissue cryopreservation was oﬀ ered to children 
submitted to gonadotoxic treatment. These patients 
are now adults and could soon request the use of their 
frozen ovarian cortex. The decision-making process for 
reimplantation is not simple. It should take into account 
the risk of reseeding cancer, which is particularly high 
in blood-borne cancers (the most common types of 
cancer in childhood). Generation of oocytes by in-vitro 
culture of primordial follicles to avoid this risk is an 
option, but such studies are still underway and clinically 
relevant data are not yet available.10 The indication for 
reimplantation is also still debated, and many authors, 
including Wallace and colleagues,5 recommend that 
the procedure be limited to fertility use only (rejecting 
its use for induction of puberty, which can be done 
with synthetic hormonal substitution), because of the 
limited lifespan of the ovary linked to ischaemia-related 
follicle depletion. 3,4
The ﬁ nal step of a story that began many years ago 
for the adult survivor of childhood cancer will therefore 
be taken by adult specialists (eg, assisted reproduction 
physicians and surgeons), who are not always familiar with 
childhood cancers. A close collaboration with paediatric 
oncologists, endocrinologists, and gynaecologists should 
be anticipated to optimise the lessons of this unique 
experience.
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Drugs targeting HER2 are central to the treatment of 
patients with HER2-positive breast cancer, and dual 
targeting of HER2 with two drugs has gained much 
attention since 2010.1 Patients with metastatic HER2-
positive breast cancer have better overall survival 
when treated with docetaxel and the two anti-HER2 
monoclonal antibodies (trastuzumab and pertuzumab, 
which bind to diﬀ erent extracellular domains of the 
HER2 kinase), than do patients treated only with 
docetaxel and trastuzumab.2 Dual targeting of HER2 is 
also supported by neoadjuvant studies. In these trials, 
a greater proportion of patients who were treated with 
chemotherapy, trastuzumab, and lapatinib (a HER1 and 
HER2 inhibitor),3–5 or with chemotherapy, trastuzumab, 
and pertuzumab6 achieved pathological complete 
response than did those treated with chemotherapy 
plus trastuzumab alone.
The phase 3, three-group NeoALTTO trial7 is one 
of the key studies to assess dual targeting of HER2. 
In NeoALTTO, investigators compared trastuzumab, 
lapatinib, and their combination as neoadjuvant and 
adjuvant treatment in a population of 455 patients 
with early HER2-positive breast cancer. The anti-HER2-
directed therapies were ﬁ rst administered alone for 
